Neximmune to present at the society for immunotherapy of cancer 36th anniversary annual meeting

Gaithersburg, md., nov. 03, 2021 (globe newswire) -- neximmune, inc. (nasdaq: nexi), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells, today announced that two abstracts have been accepted for poster presentation at the upcoming society for immunotherapy of cancer (sitc) 36th annual meeting in washington, d.c., being held november 10-14, 2021.
NEXI Ratings Summary
NEXI Quant Ranking